Literature DB >> 105016

Assessment of the efficacy of interventions to limit ischemic injury by direct measurement of intramural carbon dioxide tension after coronary artery occlusion in the dog.

L D Hillis, S F Khuri, E Braunwald, R A Kloner, D Tow, E Barsamian, P R Maroko.   

Abstract

Although numerous interventions have been shown to exert a salutary effect on the ischemic myocardium, the severity of ischemia generally has been measured by indirect techniques. In the present investigation the effect of ischemia on intramural carbon dioxide tension (PmCO(2)) was measured directly in the open-chest, anesthetized dog with a mass spectrometer during repetitive 10-min coronary artery occlusions separated by 45-min periods of reflow; simultaneously, regional myocardial blood flow in the ischemic area was measured by (127)Xenon washout. In all dogs the increase in PmCO(2) from before to 10 min after the first occlusion (DeltaPmCO(2)) exceeded that during subsequent occlusions. In those dogs not receiving an intervention (controls), DeltaPmCO(2) during the third occlusion was similar to that during the second occlusion. When propranolol, hyaluronidase, and nitroglycerin were administered to different groups of dogs before the third occlusion, each caused significantly smaller elevations in DeltaPmCO(2) than those occurring during the control second occlusion, and the combination of all three interventions induced the smallest increase in DeltaPmCO(2). Regional myocardial blood flow rose with hyaluronidase and was unchanged with propranolol, nitroglycerin, and the three drugs in combination. In contrast to these beneficial interventions, isoproterenol infused with the third occlusion caused a higher DeltaPmCO(2) than during the control second occlusion. It is concluded, first, that interventions that modify the severity of ischemia can be evaluated by measuring intramural carbon dioxide tension; second, that propranolol, hyaluronidase, and nitroglycerin reduce ischemic injury, whereas isoproterenol increases it; and third, that the combination of propranolol, hyaluronidase, and nitroglycerin exerts an additive beneficial effect on ischemia.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 105016      PMCID: PMC371923          DOI: 10.1172/JCI109284

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  44 in total

1.  NONUNIFORM DISTRIBUTION OF BLOOD FLOW AND GRADIENTS OF OXYGEN TENSION WITHIN THE HEART.

Authors:  E S KIRK; C R HONIG
Journal:  Am J Physiol       Date:  1964-09

2.  Distribution of coronary collateral flow in acute myocardial ischaemic injury: effect of propranolol.

Authors:  R A Kloner; K A Reimer; R B Jennings
Journal:  Cardiovasc Res       Date:  1976-01       Impact factor: 10.787

3.  Evaluation of precordial electrocardiographic mapping as a means of assessing changes in myocardial ischemic injury.

Authors:  J E Muller; P R Maroko; E Braunwald
Journal:  Circulation       Date:  1975-07       Impact factor: 29.690

4.  Regional myocardial functional and electrophysiological alterations after brief coronary artery occlusion in conscious dogs.

Authors:  G R Heyndrickx; R W Millard; R J McRitchie; P R Maroko; S F Vatner
Journal:  J Clin Invest       Date:  1975-10       Impact factor: 14.808

5.  On the nature of protection by propranolol against myocardial necrosis after temporary coronary occlusion in dogs.

Authors:  K A Reimer; M M Rasmussen; R B Jennings
Journal:  Am J Cardiol       Date:  1976-03-31       Impact factor: 2.778

6.  Effects of hyaluronidase and hydrocortisone on myocardial necrosis after coronary occlusion.

Authors:  E Braunwald; P R Maroko
Journal:  Am J Cardiol       Date:  1976-03-31       Impact factor: 2.778

7.  Effects of coronary perfusion during myocardial hypoxia. Comparison of metabolic and hemodynamic events with global ischemia and hypoxemia.

Authors:  A J Liedtke
Journal:  J Thorac Cardiovasc Surg       Date:  1976-05       Impact factor: 5.209

8.  Mass spectrometry for the measurement of intramyocardial gas tensions: methodology and application to the study of myocardial ischemia.

Authors:  S F Khuri; J O'Riordan; J T Flaherty; R K Brawley; J S Donahoo; V L Gott
Journal:  Recent Adv Stud Cardiac Struct Metab       Date:  1975

9.  Effects of hyaluronidase administration on myocardial ischemic injury in acute infarction. A preliminary study in 24 patients.

Authors:  P R Maroko; D M Davidson; P Libby; A D Hagan; E Braunwald
Journal:  Ann Intern Med       Date:  1975-04       Impact factor: 25.391

10.  Changes in intramyocardial ST segment voltage and gas tensions with regional myocardial ischemia in the dog.

Authors:  S F Khuri; J T Flaherty; J B O'Riordan; B Pitt; R K Brawley; J S Donahoo; V L Gott
Journal:  Circ Res       Date:  1975-10       Impact factor: 17.367

View more
  5 in total

1.  Influence of hyaluronidase on infarct size following experimental coronary occlusion of short (90') or long (24 hrs) duration.

Authors:  M Hofmann; M Hofmann; W Schaper
Journal:  Basic Res Cardiol       Date:  1980 Mar-Apr       Impact factor: 17.165

2.  Effects of recurrent ischemia on myocardial high energy phosphate content in canine hearts.

Authors:  R Lange; J S Ingwall; S L Hale; K J Alker; R A Kloner
Journal:  Basic Res Cardiol       Date:  1984 Jul-Aug       Impact factor: 17.165

3.  Local vasoactivity of oxygen and carbon dioxide in the right coronary circulation of the dog and pig.

Authors:  S W Ely; D C Sawyer; J B Scott
Journal:  J Physiol       Date:  1982-11       Impact factor: 5.182

4.  Prolonged derangements of canine myocardial purine metabolism after a brief coronary artery occlusion not associated with anatomic evidence of necrosis.

Authors:  L W DeBoer; J S Ingwall; R A Kloner; E Braunwald
Journal:  Proc Natl Acad Sci U S A       Date:  1980-09       Impact factor: 11.205

5.  Regulation of ion gradients across myocardial ischemic border zones: a biophysical modelling analysis.

Authors:  Steven Niederer
Journal:  PLoS One       Date:  2013-04-05       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.